Investment Rating - The report assigns a "Buy" rating to the company with a target price of $46.41, indicating a potential upside of 138% from the current stock price of $19.5 [2][4][31]. Core Insights - CARVYKTI sales are experiencing significant growth, with projected revenues of $1.887 billion in 2025, reflecting a year-over-year increase of 95.9%. The company is expected to achieve profitability at the company level in 2026 [3][7]. - The company has made substantial investments in production capacity, with four global manufacturing facilities. Approval for commercial production at the Raritan facility is anticipated by the end of Q1 2026, which would increase annual production capacity to 10,000 doses [8][9]. - Competitive analysis shows that while Johnson & Johnson's MajesTEC-3 trial has strong data, the patient demographics differ significantly from those in the CART-4 trial, suggesting that CART-4 patients may have more severe conditions, which could impact treatment outcomes [10][11]. Summary by Sections Financial Performance - The company reported total revenues of $285 million for 2023, with projections of $1.412 billion for 2026 and $1.863 billion for 2027, indicating substantial growth rates of 143.7% and 39.7% respectively [6][32]. - The company is expected to achieve a net profit of $418 million by 2027, with earnings per share projected to reach $1.13 [6][31]. Production Capacity - The company has invested nearly $1 billion in production facilities, with plans to expand the Gent facility in Belgium, which is expected to increase capacity to 20,000 doses by 2028 [8][9]. - The anticipated FDA approval for the Raritan facility will significantly enhance production capabilities, allowing for rapid scaling in response to market demand [9][10]. Clinical Pipeline - The company is advancing its clinical trials, with the Cartitude-5 trial for first-line non-transplant patients completed and plans to negotiate with the FDA regarding MRD negativity as a potential endpoint for Cartitude-6 [4][27]. - The Cartitude-6 trial is the only ongoing Phase III trial directly comparing CAR-T therapy with autologous stem cell transplantation for newly diagnosed multiple myeloma [28]. Market Position - The report highlights that if the company captures 15-20% of the 2-4 line patient market, it could translate to approximately 10,000 treatments annually, emphasizing the potential for Carvykti as a preferred treatment option [15]. - The competitive landscape indicates that Carvykti's efficacy data provides a significant advantage, particularly for patients seeking long-term remission and potential cures [15][20].

Company Overview - Legend Biotech (LEGN) is rated as a "Buy" with a target price of $46.41, representing a potential upside of 138% from the current price of $19.5[5] - The company is expected to achieve profitability in 2026, driven by the sales growth of its product CARVYKTI[5] Financial Performance - CARVYKTI generated $1.887 billion in revenue for 2025, with a year-on-year growth of 95.9%[10] - The company forecasts total revenue of $1.412 billion for 2026, reflecting a growth rate of 39.7%[9] - Legend Biotech's earnings per share (EPS) is projected to turn positive at $0.28 in 2026, after losses in previous years[9] Production Capacity - The company has four global production facilities, with an expected annual capacity of 10,000 doses upon FDA approval in Q1 2026[5] - A $200 million investment is planned to expand the production capacity in Ghent, Belgium, aiming for 20,000 doses by 2028[5] Competitive Landscape - Legend Biotech's CART-4 trial includes a higher percentage of more severe patients compared to Johnson & Johnson's MajesTEC-3 trial, indicating a competitive edge in clinical data[6] Valuation Metrics - A discounted cash flow (DCF) analysis assumes a weighted average cost of capital (WACC) of 10% and a perpetual growth rate of 0%, leading to a target price of $46.41[8]

SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Core Viewpoint - Legend Biotech (NASDAQ:LEGN) is identified as one of the biotechnology stocks with significant upside potential, supported by favorable FDA guidance regarding approval endpoints for multiple myeloma treatments [1][2]. Group 1: Analyst Ratings and Price Targets - RBC Capital maintained an Outperform rating on Legend Biotech with a price target of $66, highlighting the FDA's draft guidance that supports the use of Minimal Residual Disease (MRD) negativity and complete response rate for expedited approval [1]. - Raymond James also reaffirmed its Outperform rating on Legend Biotech, setting a higher price target of $86, attributing its positive outlook to the same FDA guidance and emphasizing the importance of these endpoints in less aggressive forms of multiple myeloma [2]. Group 2: Company Overview - Legend Biotech is a commercial-stage biopharmaceutical company focused on developing innovative therapies, particularly in the area of cell therapy for serious diseases such as hematologic malignancies and solid tumors [3].

Group 1 - Legend Biotech Corp (NASDAQ:LEGN) is recognized as one of the 13 Best Revenue Growth Stocks to buy currently [1] - The company appointed Robin Meng, chairman and executive director of major shareholder GenScript, as a Class III director, replacing Li Zhu [1] - Directors Li Zhu and Yau Wai Man Philip resigned from the board, with the company stating that these departures were not related to any operational or policy disputes [3] Group 2 - H. C. Wainwright lowered the price target for Legend Biotech's stock from $60 to $50, while TD Cowen downgraded the stock from Buy to Hold with a price target of $21 [3] - Legend Biotech reported preliminary net trade sales of approximately $555 million for its CARVYKTI multiple myeloma cell therapy for the quarter ended December 31, 2025 [3] - The company is engaged in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications [3]

Core Viewpoint - The article discusses the significant progress in China's innovative drug development, highlighting the increase in the number of new drugs approved and the growing competitiveness of Chinese pharmaceutical companies in both domestic and international markets [4][16]. Group 1: Growth of Innovative Drugs - In 2024, the number of domestically developed Class 1 new drugs in China reached 40, a substantial increase from just 9 in 2018 [2][3][4]. - Since the beginning of the 14th Five-Year Plan, 113 innovative drugs have been approved, which is 2.8 times the number approved during the 13th Five-Year Plan [4]. - As of August 2024, there are 910 new drugs available in China, indicating a robust growth in the pharmaceutical market [6]. Group 2: Clinical Trials and Breakthroughs - In a head-to-head clinical trial, the drug Ivoris (依沃西单抗) developed by Kangfang Biopharma outperformed the global best-selling cancer drug, Pembrolizumab (K drug), marking a significant achievement for Chinese innovation [7][9]. - The global sales of Pembrolizumab reached $29.482 billion in 2024, underscoring the competitive landscape [8]. Group 3: Market Dynamics and International Expansion - Chinese innovative drugs are not only performing well domestically but are also gaining traction in international markets, with products like Sidakio (西达基奥仑赛) achieving $1.596 billion in cumulative sales since its launch [12][13]. - The total transaction scale of technology licensing by Chinese pharmaceutical companies exceeded $34 billion in 2024, indicating a shift towards international collaboration [14][15]. Group 4: R&D Landscape and Challenges - As of August 2024, there are 5,380 new drug candidates in development in China, accounting for over one-third of the global pipeline [18]. - The average cost of developing an innovative drug is around $1 billion, with a typical development timeline of 10 years [20][21]. - The efficiency of drug development in China is improving, with preclinical phases taking 12-20 months compared to 24-36 months internationally [23]. Group 5: Policy Support and Ecosystem - The Chinese government has implemented various policies since 2008 to support innovative drug development, including expedited approval processes and financial incentives [28][29]. - The combination of government support, industry collaboration, and technological advancements is creating a conducive environment for innovation in the pharmaceutical sector [41]. Group 6: Future Outlook - The article emphasizes that the development of innovative drugs in China has made significant strides over the past decade, transitioning from imitation to innovation [42]. - The government's continued support for innovative drugs is expected to enhance the industry's growth and provide hope for patients [42].

Company Overview - Legend Biotech Corporation (NASDAQ: LEGN) is a global biotechnology company focused on developing and commercializing advanced cell therapies, particularly CAR-T treatments for cancer, such as CARVYKTI for multiple myeloma [3]. Sales Performance - In Q4, Carvykti sales reached $555 million, which fell short of the consensus estimate of $582 million. This sales miss has been attributed to holiday seasonality and sluggish demand influenced by toxicity concerns and increasing competition [2]. Analyst Ratings and Price Targets - H.C. Wainwright lowered the price target for LEGN from $60 to $50 but maintained a Buy rating, viewing the recent pullback as a buying opportunity due to Carvykti's curative potential [1]. - Conversely, TD Cowen downgraded Legend Biotech from Buy to Hold and reduced the price target from $62 to $21, citing concerns over demand and competition affecting sales [2].

Core Viewpoint - Legend Biotech Corporation (NASDAQ:LEGN) is viewed positively by analysts, with Deutsche Bank and Cantor Fitzgerald both maintaining bullish ratings and setting price targets of $60 and $74 respectively, driven by expectations of strong clinical trial results and significant sales growth in its oncology pipeline [1][4]. Group 1: Analyst Ratings and Price Targets - Deutsche Bank reiterated a Buy rating on Legend Biotech and set a price target of $60, anticipating topline results from its first in-vivo CAR T program by year-end [1]. - Cantor Fitzgerald reaffirmed an Overweight rating with a price target of $74, highlighting the expected 100% year-over-year sales increase of Carvykti to $2 billion [4]. Group 2: Clinical Development and Pipeline - Initial preclinical data indicate robust dose-dependent CAR-T expansion in non-human primates, with sustained peripheral B-cell elimination observed from day 8 to day 36, suggesting in vivo CAR-T cells have properties akin to traditional CAR-T treatments [2]. - Legend Biotech aims to achieve profitability by 2026 while continuing to develop its pipeline, focusing on in vivo and allogeneic CAR-T therapies [3]. Group 3: Company Overview - Legend Biotech is a global clinical-stage biotechnology company dedicated to discovering, developing, and commercializing novel cell therapies, primarily targeting cancer and severe diseases, leveraging technologies like CAR-T cell therapy [5].

Core Insights - Legend Biotech (LEGN) is scheduled to present six new poster analyses on Carvykti at the 2026 Tandem Meetings from February 4th to 7th in Salt Lake [1] Company Focus - The company aims to identify promising biotechnology firms that are innovating through unique mechanisms of action, first-in-class therapies, or platform technologies that could reshape treatment paradigms [1] - The approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1] Industry Context - The biotech sector is characterized by breakthrough science that can lead to significant returns, but it also requires careful scrutiny due to inherent risks [1]